Elanco Animal Health Inc (ELAN)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
- Ticker
- ELAN
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $12.86B
- 52-week range
- $19.40 - $27.98
Valuation
- Share price
- $25.74 (close of Nov 6, 2026)
- P/E (TTM)
- -85.80x
- Price to book
- 1.94x
- Price to free cash flow
- 31.53x
- Enterprise value
- $15.92B
- Book value per share
- $13.26
Price performance
| Period | Change |
|---|---|
| 1 day | +8.70% |
| 5 days | +11.62% |
| 1 month | +14.50% |
| 3 months | +6.36% |
| 6 months | -1.68% |
| Year to date | +13.74% |
| 1 year | +19.61% |
| 3 years | +175.00% |
| 5 years | -24.49% |
| All time | -28.50% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 9.89%
- Shares short
- 31.11M
- Days to cover
- 6.39
- Change since prior report
- -16.59%
- Source
- FINRA consolidated short interest
Profitability and growth
- Return on equity
- -3.54%
- Return on invested capital
- -0.04%*
- Return on assets
- -1.74%
- Return on capital employed
- -0.03%*
- Gross margin
- 54.99%
- Net margin
- -4.92%
- EBITDA margin
- 14.34%
- Revenue growth
- 6.22%
- Net income growth
- -168.64%
- Free cash flow growth
- -27.92%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.17%
- Current ratio
- 2.09x
- Net debt to EBITDA
- 3.57x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $4.71B
- Cost of revenue
- $2.12B
- Gross profit
- $2.59B
- EBITDA
- $676.00M
- Net income
- -$232.00M
- Earnings per share
- $-0.47
- Research and development
- $368.00M
- Interest expense
- $220.00M
- Shares outstanding
- 496.40M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $4.71B | $2.59B | -$232.00M | -$0.47 |
| 2024-12-31 | $4.44B | $2.44B | $338.00M | $0.68 |
| 2023-12-31 | $4.42B | $2.49B | -$1.23B | -$2.50 |
| 2022-12-31 | $4.41B | $2.50B | -$78.00M | -$0.16 |
| 2021-12-31 | $4.76B | $2.63B | -$483.00M | -$0.99 |
| 2020-12-31 | $3.27B | $1.61B | -$574.00M | -$1.30 |
| 2019-12-31 | $3.07B | $1.60B | $68.00M | $0.18 |
| 2018-12-31 | $3.07B | $1.49B | $86.50M | $0.28 |
| 2017-12-31 | $2.89B | $1.40B | -$310.70M | -$1.06 |
| 2016-12-31 | $2.91B | $1.50B | -$47.90M | -$0.16 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 54.99% | -4.92% | -3.54% | -0.04%* |
| 2024-12-31 | 54.88% | 7.61% | 5.54% | 5.50%* |
| 2023-12-31 | 56.28% | -27.87% | -19.78% | -7.65%* |
| 2022-12-31 | 56.63% | -1.77% | -1.07% | 1.24%* |
| 2021-12-31 | 55.25% | -10.14% | -6.43% | -1.77%* |
| 2020-12-31 | 49.07% | -17.54% | -6.79% | -2.87%* |
| 2019-12-31 | 52.13% | 2.21% | 1.23% | 1.84%* |
| 2018-12-31 | 48.68% | 2.82% | 1.66% | 1.51%* |
| 2017-12-31 | 48.29% | -10.75% | -3.99% | -2.99%* |
| 2016-12-31 | 51.64% | -1.64% | -0.68% | - |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $545.00M | $3.76B |
| 2024-12-31 | $468.00M | $4.28B |
| 2023-12-31 | $352.00M | $5.74B |
| 2022-12-31 | $345.00M | $5.45B |
| 2021-12-31 | $638.00M | $6.03B |
| 2020-12-31 | $495.00M | $5.57B |
| 2019-12-31 | $334.00M | $2.33B |
| 2018-12-31 | $474.80M | $2.44B |
| 2017-12-31 | $323.40M | - |
| 2016-12-31 | $258.80M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $284.00M | $68.00M |
| 2024-12-31 | $394.00M | $55.00M |
| 2023-12-31 | $131.00M | $46.00M |
| 2022-12-31 | $281.00M | $59.00M |
| 2021-12-31 | $324.00M | $66.00M |
| 2020-12-31 | -$176.00M | $47.00M |
| 2019-12-31 | $84.00M | $49.00M |
| 2018-12-31 | $352.80M | $26.00M |
| 2017-12-31 | $75.20M | $25.00M |
| 2016-12-31 | $45.60M | $20.40M |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-06 | Sep 2026 | $0.20 |
| 2026-08-05 | Jun 2026 | $0.27 |
| 2026-05-06 | Mar 2026 | $0.34 |
| 2026-02-24 | Dec 2025 | $0.11 |
| 2025-11-05 | Sep 2025 | $0.13 |
| 2025-08-07 | Jun 2025 | $0.20 |
| 2025-05-07 | Mar 2025 | $0.31 |
| 2025-02-25 | Dec 2024 | $0.15 |
Filings and sources
- Company website
- elanco.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Teva Pharmaceutical Industries Ltd (TEVA) · Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades